http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101569966-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-05 |
| filingDate | 2013-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101569966-B1 |
| titleOfInvention | Heterovalent inhibitors targeting N-end Rule Pathway and its use |
| abstract | The present invention discloses compounds of formula (I) and compositions for inhibiting N-end Rule pathways comprising the same. The compounds according to the present invention are heterologous inhibitors that simultaneously target two active sites of mammalian N-end rule E3 ligase with UBR box and ClpS box recognizing type 1 and type 2 substrates, respectively, And can effectively control the N-end Rule pathway. Thus, it is useful to treat diseases associated with abnormal proteolytic degradation, for example, heart diseases and neurodegenerative diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11666661-B2 |
| priorityDate | 2013-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 329.